FPI-1175

FPI-1175 is a humanized monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R). It acts as an IGF-1R antagonist, blocking the activity of this receptor, which is implicated in the development and progression of various solid tumors. FPI-1175 was developed by Fusion Pharmaceuticals and has been studied both as a standalone agent and as part of theranostic regimens to enhance tumor targeting for radiopharmaceutical therapies. Its primary mechanism involves inhibiting IGF-1R signaling, thereby potentially reducing tumor growth and survival. Clinical trials have evaluated its use in adrenocortical carcinoma, endometrial carcinoma, HER2-negative breast cancer, and other locally advanced malignant solid neoplasms[1][4][6].